City of Hope | Strategic Alliance Partners

March 29, 2024

In this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.

March 28, 2024

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

March 28, 2024

Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.

March 28, 2024

Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.

March 27, 2024

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

March 25, 2024

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.

March 22, 2024

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

March 21, 2024

Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.

March 21, 2024

Side effect profiles driven by fruquintinib use are discussed.

March 18, 2024

Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.

March 14, 2024

Initial antitumor activity and safety data have been observed in the phase 1 portion of a phase 1/2a trial of IMM-1-104 in RAS-mutant solid tumors.

March 14, 2024

Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.

March 14, 2024

Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.

March 07, 2024

Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.

March 07, 2024

Medical experts provide key takeaways and impacts from the FRESCO-2 study.

March 01, 2024

The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.

February 29, 2024

Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.

February 29, 2024

Key safety considerations for the use of fruquintinib are explored.

February 23, 2024

Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.

February 23, 2024

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.